Machuca A, Gutiérrez M, Mur A, Soriano V
Service of Infectious Diseases, Instituto de Salud Carlos III, Madrid, Spain.
Antivir Ther. 1998;3(3):187-9.
Failure to recognize infection caused by human immunodeficiency virus type 1 (HIV-1) group O variants has been described using both serological and genetic techniques. Moreover, the monitoring of response to antiretroviral therapy is difficult in persons carrying this infection since most currently available tests for quantifying viral load are not reliable for group O viruses. Considering the low level of divergence between the p24 proteins of group M and O viruses, we have examined whether the quantification of circulating p24 antigenaemia might be used as a surrogate marker of response to therapy in three subjects with HIV-1 group O infection treated with antiretroviral drugs. In summary, all three patients showed a significant decline in circulating plasma p24 antigenaemia, although only one achieved undetectable levels. The decline in p24 antigenaemia was parallel to an increase in the CD4 count and was associated with an improvement in clinical status.
利用血清学和基因技术均已发现，无法识别由1型人类免疫缺陷病毒（HIV-1）O组变体引起的感染。此外，对于感染这种病毒的人来说，监测抗逆转录病毒疗法的疗效很困难，因为目前大多数用于定量病毒载量的检测方法对O组病毒并不可靠。鉴于M组和O组病毒的p24蛋白之间差异程度较低，我们研究了在三名接受抗逆转录病毒药物治疗的HIV-1 O组感染患者中，循环p24抗原血症的定量是否可作为治疗反应的替代标志物。总之，所有三名患者的循环血浆p24抗原血症均显著下降，尽管只有一人降至检测不到的水平。p24抗原血症的下降与CD4细胞计数的增加平行，并与临床状况的改善相关。
